1242268-17-2

Usage

Uses

Used in Pharmaceutical Research:
6-O-tert-butyl 2-O-ethyl 6-azaspiro[2.5]octane-2,6-dicarboxylate is used as a research compound for exploring its potential biological activity and applications in drug development. Its unique structure may offer novel therapeutic opportunities.
Used in Drug Development:
In the pharmaceutical industry, 6-O-tert-butyl 2-O-ethyl 6-azaspiro[2.5]octane-2,6-dicarboxylate is used as a starting material or intermediate in the synthesis of new drugs. Its complex structure could lead to the discovery of innovative medications with specific therapeutic effects.
Further research and testing are required to fully understand the properties and potential uses of 6-O-tert-butyl 2-O-ethyl 6-azaspiro[2.5]octane-2,6-dicarboxylate, as its current applications are based on its structural characteristics and the possibilities they present in the field of medicinal chemistry.

Upstream product

• 1774-47-6 trimethylsulfoxonium iodide 
• 135716-08-4 tert-butyl 4-(2-ethoxy-2-oxoethylidene)piperidine-1-carboxylate 

Downstream Products

• 871727-05-8 (±)-6-(tert-butoxycarbonyl)-6-azaspiro[2.5]octane-1-carboxylic acid 
• 1453272-51-9 tert-butyl 1-[[(1S)-1-phenylethyl]carbamoyl]-6-azaspiro[2.5]octane-6-carboxylate 
• 1160247-14-2 tert-butyl 1-carbamoyl-6-azaspiro[2.5]octane-6-carboxylate 
• 1416173-78-8 tert-butyl 1-{3-[4-(methanesulfonyl)phenoxy]propyl}-6-azaspiro[2.5]octane-6-carboxylate 
• 1416173-81-3 tert-butyl 1-{2-[4-(methanesulfonyl)phenoxy]ethyl}-6-azaspiro[2.5]octane-6-carboxylate 

Relevant academic research and scientific papers

COMBINATIONS COMPRISING BENZODIOXOL AS GLP-1R AGONISTS FOR USE IN THE TREATMENT OF NASH/NAFLD AND RELATED DISEASES

In part, the invention provides a new combination comprising (1) a GLP-1R agonist and (2) an ACC inhibitor or a DGAT2 inhibitor, or a KHK inhibitor or FXR agonist. The invention further provides new methods for treating diseases and disorders, for example, fatty liver, nonalcoholic fatty liver disease, nonalcoholic steatohepatitis, nonalcoholic steatohepatitis with liver fibrosis, nonalcoholic steatohepotitis with cirrhosis, and nonalcoholic steatohepatitis with cirrhosis and with hepatocellular carcinoma or with a metabolic-related disease, obesity, and type 2 diabetes, for example, using the new combination described herein.

SPIROPIPERIDINE ALLOSTERIC MODULATORS OF NICOTINIC ACETYLCHOLINE RECEPTORS

The present disclosure relates to compounds of formula (I) that are useful as modulators of 7α nAChR, compositions comprising such compounds, and the use of such compounds for preventing, treating, or ameliorating disease, particularly disorders of the central nervous system such as cognitive impairments in Alzheimer's disease, Parkinson's disease, and schizophrenia, as well as for L-DOPA induced-dyskinesia and inflammation.

GLP-1 Receptor Agonists and Uses Thereof

Provided herein are 6-carboxylic acids of benzimidazoles and 4-aza-, 5-aza-, and 7-aza-benzimidazoles as GLP-1R agonists, processes to make said compounds, and methods comprising administering said compounds to a mammal in need thereof.

GLP-1 RECEPTOR AGONISTS AND USES THEREOF

Provided herein are 6-carboxylic acids of benzimidazoles and 4-aza-, 5-aza-, and 7-aza- benzimidazoles as GLP-1R agonists, processes to make said compounds, and methods comprising administering said compounds to a mammal in need thereof.

HETEROARYL PYRIDONE AND AZA-PYRIDONE AMIDE COMPOUNDS

Heteroaryl pyridone and aza-pyridone amide compounds of Formula (I) are provided, and various substituents including stereoisomers, tautomers, and pharmaceutically acceptable salts thereof, useful for inhibiting Btk, and for treating cancer and immune disorders such as inflammation mediated by Btk. Methods of using compounds of Formula I for in vitro, in situ, and in vivo diagnosis, and treatment of such disorders in mammalian cells, or associated pathological conditions, are disclosed.

AMIDO SPIROCYCLIC AMIDE AND SULFONAMIDE DERIVATIVES

Provided are amido spirocyclic amide and sulfonamide compounds, pharmaceutical compositions comprising such compounds, and methods of treatment using such compounds.